Case Reports in Medicine

Case Reports in Medicine / 2016 / Article

Case Report | Open Access

Volume 2016 |Article ID 6405840 | 3 pages | https://doi.org/10.1155/2016/6405840

Systemic Sarcoidosis Unmasked by Cushing’s Disease Surgical Treatment

Academic Editor: Christian Koch
Received07 Apr 2016
Revised22 Jun 2016
Accepted26 Jun 2016
Published25 Jul 2016

Abstract

Diseases responsive to glucocorticoids, like sarcoidosis, are rarely masked by Cushing’s syndrome. An ACTH secreting pituitary adenoma is a possible cause of Cushing’s syndrome and its resection can make a subclinical sarcoidosis clear. Only few cases of sarcoidosis following the treatment of hypercortisolism are reported in literature. We report a case of sarcoidosis after the resection of an ACTH secreting pituitary adenoma.

1. Introduction

Follow-up evaluations of surgically operated pituitary adenoma patients are often staged multidisciplinarily between different specialists. We would like to share here a case of an unusual complication following transsphenoidal surgery for Cushing’s disease that may arise at midlong follow-up timing to warn all the pituitary-related specialists.

2. Case Report

A 33-year-old woman had a 10-month history of amenorrhea and asthenia and weight gain (15 kgs). On physical examination, the patient was severely obese (127 kg), with predominantly central disposal of fat, abdominal purple striae, hirsutism, and dorsal hump. Blood tests revealed high levels of cortisol (1510 μg/dL): basal and dynamic pituitary function evaluation showed a normal value of ACTH with discrete response to stimulation with DDAVP, elevated cortisol with failure to respond to the CRH test stimulus, elevated urinary free cortisol, PTH elevated with normal serum calcium, and deficient values of gonadotropins and ovarian hormones. An MRI study completed with thin section dynamic contrast-enhanced sequences showed the presence of a pituitary microadenoma (Figure 1(a)). No other alterations were evident at preoperative imaging studies (Figure 2). A diagnosis of Cushing’s disease was posed and she was subjected to endoscopic transsphenoidal surgery. The postoperative course was characterized by transient diabetes insipidus and rib pain caused by multiple osteoporosis-related rib fractures. She was discharged on the fifth postoperative day. First-year follow-up endocrinological evaluations were at 1, 5, 8, and 12 months. Yet after the first month, serum levels of ACTH and urinary free cortisol were to the lower limits of standard with good response to the stimulus testing; no other major pituitary malfunctions were present. Cortisol replacement was continued and progressively tapered during the follow-up. One year after intervention, though, she noticed the presence of painless, firm, subcutaneous nodules on both hands and elbows and on the left knee, associated with asthenia and unspecific malaise. Body weight was diminished (−13 kgs), diabetes was under good control, and there were no concomitant infectious diseases. A biopsy of one of the nodules was performed and histological examination showed nonnecrotizing epithelioid cell granuloma, consistent with the diagnosis of sarcoidosis (Figures 1(c) and 1(d)). She was then subjected to an X-ray study, finding an enlargement of the hilar shadows on both sides. A CT scan with contrast medium showed the presence of multiple enlarged lymph nodes in the hilar-mediastinal region bilaterally, with a maximum diameter in subcarinal area of approximately 4 cm (Figure 1(b)). There were no pleural or parenchymal lesions with characters of activity or signs of interstitial disease. Pulmonary function tests were normal. QuantiFERON-TB Gold analysis, M. tuberculosis complex PCR amplification test, and screening blood tests for autoimmune diseases were negative, while serum ACE was 40.1 Ui/L (8–52). Cholecalciferol supplementation has been provided to the patient on a monthly basis to correct deficient 25-hydroxy vitamin D level found before surgery. Subsequent PTH and calcium levels were interpreted as secondary to underlying sarcoid. At skin nodules first-time appearance, the patient was still on low doses of daily steroid therapy (cortisone acetate 12.5 mg/day). Cortisone acetate therapy was then suggested until its permanent discontinuation 5 months later (Table 1). Skin nodules progressively regressed in five months. Radiological and endocrinological follow-up at 5 years showed no signs of disease progression or recurrence for both sarcoidosis and Cushing’s disease; no therapy is prescribed and body weight dropped a total of 25 kgs.


1 month5 months8 months12 months18 months24 months36 months

Calcium (mg/dL, normal range 8.5–11.0)9.28.98.910.79.810.19.3
Intact parathyroid hormone (pg/mL, normal range 12.0–72.0)11447.415.455.343.7
25-Hydroxy vitamin D (ng/mL)27.730.134.8
Cortisone acetate (mg/day)2512.512.512.5///

3. Discussion

Corticoids are a common treatment option for many immune-related diseases. New onset or worsening of many of these diseases after Cushing syndrome remission has been reported in the literature including arthritis, vasculitis, dermatitis, celiac disease, and systemic lupus erythematosus [1]. Sarcoidosis is a systemic disorder of unknown etiology whose treatment is often successful with continuous glucocorticoid prescription. To date, we found only five other previous reports of sarcoidosis after Cushing’s disease surgical treatment [15]. All of the cases (4 females, 2 males) had skin and lung involvement while three cases had also mediastinal masses and one had a localisation in the eye. Since mean delay to onset of symptoms is 14.5 months (3–48), a strict follow-up and widespread knowledge of this potentially harmful condition in both endocrinological and neurosurgical communities are to be recommended.

Competing Interests

The authors declare that there are no competing interests.

References

  1. F. Da Mota, C. Murray, and S. Ezzat, “Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 10, pp. E1670–E1674, 2011. View at: Publisher Site | Google Scholar
  2. K. Takenaka, T. Yanase, R. Takayanagi, M. Haji, S. Ikuyama, and H. Nawata, “Cushing's disease preceding sarcoidosis,” Internal Medicine, vol. 34, no. 6, pp. 580–583, 1995. View at: Publisher Site | Google Scholar
  3. A. V. Marzano, G. Gasparini, R. Caputo, and E. Alessi, “Subcutaneous sarcoidosis following hypophysectomy for pituitary microadenoma inducing Cushing's disease,” International Journal of Dermatology, vol. 37, article 798, no. 10, 1998. View at: Google Scholar
  4. J. C. Fichtel, A. K. Wiggins Duckworth, T. Soares, and J. L. Lesher Jr., “Subcutaneous sarcoidosis presenting after treatment of Cushing's disease,” Journal of the American Academy of Dermatology, vol. 54, no. 2, pp. 360–361, 2006. View at: Publisher Site | Google Scholar
  5. S. Schaefer, S. Meyer, C. C. Brueck et al., “Sarcoidosis following Cushing's syndrome: a report of two cases and review of the literature,” Experimental and Clinical Endocrinology and Diabetes, vol. 118, no. 3, pp. 147–150, 2010. View at: Publisher Site | Google Scholar

Copyright © 2016 Daniele Bongetta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

947 Views | 294 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.